Belbuca

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Pain

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Other / comorbidity
NCT05427981 · New York State Psychiatric Institute
2022-10-10 – 2024-01-14 · Suicidal Ideation, Major Depressive Disorder
What this study did
Phase 2 (1)
Other / comorbidity
NCT05778591 · University of California, Los Angeles
2024-05-17 – 2027-03-01 · Schizophrenia
What this study did
Phase 1 (2)
Other / comorbidity
NCT07799571 · Natasha Archer
2027-01 – 2032-10 · Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
What this study did
NCT03996694 · BioDelivery Sciences International
2019-07-23 – 2019-10-27 · Respiratory Depression
What this study did
Phase 4 (1)
Chronic Pain
NCT05419297 · Carolinas Pain Institute
2022-08-03 – 2023-07 · Back Pain Lower Back Chronic, Chronic Pain
What this study did

Competitive landscape

This drug's own stage for Chronic Pain: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Belbuca: this drugApprovedSmall moleculeOpioid receptors (mu-opioid receptor partial agonist, kappa-opioid receptor antagonist)not yet gradedNo reviewed efficacy summary in this indication
Oxycodone (Xtampza ER)ApprovedSmall moleculeOpioid receptors (mu-opioid receptor)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Belbuca to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2SchizophreniaRecruiting
Est. primary completion 2026-12-01 · NCT05778591 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 1Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children …Not yet recruiting
Est. primary completion 2031-10 · NCT07799571 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

December 2025ApprovalFDA updates Boxed Warning on Belbuca (NDA207932)
US, FDA · FDA · Source ↗